Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02611102
Other study ID # 404482-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 8, 2016
Est. completion date March 2022

Study information

Verified date April 2023
Source Walter Reed National Military Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine the effects on lipoprotein profiles of high dose concentrated dietary SFA (saturated fatty acids) (from MCT (medium-chain triglyceride) oil + butter) in combination added to coffee. The study will be conducted as a RCT in healthy adults without cardiometabolic disease or conditions that influence lipoprotein metabolism or other specific dietary recommendations.


Description:

Research Design A prospective randomized controlled interventional study Methodology /Technical Approach A total of up to 60 subjects will be recruited to allow for completion of the study by a minimum of 17 subjects per arm. Subjects will be randomized to one of two groups in a 1:1 ratio. Recruited subjects will be adult coffee drinkers between the ages of 18-45 without hyperlipidemia and without criteria for diabetes or pre-diabetes. Subjects will have baseline weight, waist circumference (WC), and blood-pressure (BP) measurements obtained. Subjects will have baseline fasting lipids,, CMP,HbA1c,TSH,and hsCRP. The subjects will be stratified by gender and randomized to receive one of two dietary regimens: 1) coffee (< 50 kcal of added creamer/sweetener) or 2) coffee with butter + medium-chain triglyceride (MCT) oil combination (2 tbsp. MCT containing 230kcal and 28gm fat+ 2 tbsp butter containing 200kcal and 22gm fat). The drink will be consumed daily over a 4 week period. Dietary history will be evaluated by via the ASA24website (http://appliedresearch.cancer.gov/asa24/). At 6 and 12 weeks post-consent, baseline labs will be repeated. The primary outcome is change in apolipoprotein B between groups. Secondary outcomes include changes in lipids, WC, BP, HbA1c, and FBG. Exploratory analysis will include changes in dietary macronutrient load and subgroup analysis of effects related to dietary patterns. Primary objective: 1. Evaluate clinically and statistically significant changes of apoB number in healthy adults who consume coffee with butter and MCT oil. Secondary objectives: 1. Evaluating change in: 1. non-HDL-c 2. LDL-c 3. triglycerides 4. BP 5. waist circumference 6. FBG 7. HbA1c Exploratory objective: 1. Change in macronutrient profiles of dietary patterns. Our null hypothesis is that the addition of butter and medium-chain triglyceride oil at proposed doses has no clinically significant effects on atherogenic lipoproteins, namely apo lipoprotein B particles (apoB).


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date March 2022
Est. primary completion date March 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. DoD healthcare beneficiaries 2. willing to drink 2 to 4 cups of coffee daily 3. between the ages of 18 to 45 4. serum LDL-c < 160, 5. non-HDL-c < 190 6. apoB < 120 Exclusion Criteria: 1. BMI > 30kg/m2 or < 20kg/m2 or waist circumference > 102cm (males) or 88cm (females) 2. Triglycerides > 150 3. Hypertension defined as SBP > 150, DBP > 90 or on treatment for high blood pressure 4. Chronic liver disease defined by any clinical or a history of serum AST or ALT > 3 times ULN 5. Kidney disease defined as a GFR <90 ml/min or history of nephritic syndrome 6. Impaired glucose metabolism defined as HbA1c > 5.6, FBG > 99, or 2-hour OGTT > 139 7. Any known malignancy 8. Known malabsorption disorder to include inflammatory bowel disease, celiac disease, cystic fibrosis, history of gastric bypass 9. Hypothyroidism per lab evaluation at baseline 10. Pregnancy 11. Polycystic Ovary Syndrome or irregular menstrual periods 12. Subjects taking certain medications such as glucocorticoids, immunosuppressants (cyclosporine, sirolimus, etc.), tamoxifen, androgens, antipsychotics, hydrochlorothiazide, retinoids, beta-blockers, statins, bile acid sequestrants, niacin, fibrates, ezetimibe, high dose fish oil (>1gm/day epa + dha), or any other supplement or pharmacologic agent known to alter lipoproteins a. If on hormonal contraceptives, lipid panel must be stable over the past 12-24 months 13. Cushing's syndrome per medical history or clinical suspicion 14. HIV per medical history 15. Chronic Inflammatory Disorders such as, but not limited to, SLE, RA, IBD per medical history 16. History of tobacco use within the previous 12 months to include cigarettes, e-cigarettes, chewing tobacco, cigars, and pipes. 17. History of marijuana use within the previous 12 months 18. Active intentional weight loss of over 5% in the past 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
MCT oil + Butter in Coffee
2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.

Locations

Country Name City State
United States Walter Reed National Military Medical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
Walter Reed National Military Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in apolipoprotein B Evaluate clinically and statistically significant changes of apoB number in healthy adults who consume coffee with butter and MCT oil. Baseline and 6 weeks
Secondary non-HDL-c Evaluating change in non-HDL_c 6 weeks
Secondary LDL-c Evaluating change in LDL-c 6 weeks
Secondary triglycerides Evaluating change in triglycerides 6 weeks
Secondary Blood pressure Evaluating change in blood pressure 6 weeks
Secondary waist circumference Evaluating change in waist circumference 6 weeks
Secondary Fasting Blood Glucose Evaluating change in fasting blood glucose 6 weeks
Secondary HbA1c Evaluating change in HbA1c 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects Phase 1
Completed NCT03213288 - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status N/A
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02979704 - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Phase 2/Phase 3
Completed NCT02569814 - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Phase 1
Completed NCT02280590 - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia Phase 4
Completed NCT02428998 - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults N/A
Completed NCT01678183 - Financial Incentives for Medication Adherence N/A
Completed NCT01426412 - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol Phase 1
Completed NCT01694446 - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose N/A
Completed NCT01131832 - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols Phase 4
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Completed NCT00758303 - A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Phase 2/Phase 3
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Completed NCT00362206 - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin Phase 3
Terminated NCT00299169 - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes Phase 4
Completed NCT00701454 - Survey of Thai-Muslim Health Status N/A
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A